Prospector
Profile
07.1427
|
| |
| Senesco Technologies, Inc. |
NAICS |
541710 |
| 303 George Street, Suite 420
New Brunswick, NJ 08901 |
Description |
Biotechnology |
| (732) 296-8400 |
Employees |
24 |
| http://www.senesco.com/ |
Revenue |
(mil) |
0.3000 |
| |
Income |
(mil) |
-3.2510 |
| |
Assets |
(mil) |
3.3210 |
| |
Liability |
(mil) |
0.6320 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Goldstein Golub Kessler LLP expressed doubts on the ability of Senesco Technologies, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company has incurred recurring losses from operations and has an accumulated deficit of $25,621,540 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company has 15 issued patents from the United States Patent and Trademark Office (PTO) and 12 issued patents from foreign countries including 7 from New Zealand, 2 from Australia, 1 from Mexico and 1 from Hong Kong. In addition, the Company has a wide variety of patent applications, including divisional applications and continuations-in-part, in process with the U.S. PTO and internationally. The Company intends to continue its strategy of enhancing these new patent applications through the addition of data as it is collected. [SEC Filing 10-K 09-28-07]
|
| |
|
Description:
The Company engages in the research and development of genetic technologies for commercial agriculture and to treat medical conditions in humans.
|
| |
|
Officers:
Ruedi Stalder (Chair); Bruce C. Galton (Pres. & CEO); Joel Brooks (CFO); John E. Thompson (EVP, Chief Scientific Officer & Dir.); Christopher Forbes (Dir.); Thomas C. Quick (Dir.); David Rector (Dir.); Jack Van Huls (Dir.); John Braca (Dir.)
|
| |
|
Auditor:
Goldstein Golub Kessler LLP
|
| |
|
Securities:
Common Stock-Symbol SNT; AMEX;
17,473,694 common shares outstanding as of September 15, 2007.
|
| |
| |
| |
| return to main page |
